Concurrent chemoradiotherapy with additional chemotherapy for nasopharyngeal carcinoma: A pooled analysis of propensity score‐matching studies

xlomafota13 shared this article with you from Inoreader Concurrent chemoradiotherapy with additional chemotherapy for nasopharyngeal carcinoma: A pooled analysis of propensity score‐matching studies Via Head & Neck Abstract Objective To determine the benefits of adding induction chemotherapy (IC) and adjuvant chemotherapy (AC) to concurrent chemoradiotherapy (CCRT) for nasopharyngeal carcinoma (NPC) based on propensity score‐matching (PSM) studies. Methods Eligible PSM studies were searched in the PubMed, Web of Science, and Embase databases from inception to September 1, 2020. The primary endpoints included overall survival (OS), distant metastasis‐free survival (DMFS), and locoregional recurrence‐free survival (LRFS). Results A total of 14 trials consisting of 4086 participants were included. Significant benefits were observed between IC + CCRT and CCRT for OS (hazard ratio [HR], 0.76; 95% confidence interval [CI]: 0.64–0.91) and DMFS (HR, 0.77; 95% CI: 0.64–0.94) with the exception of LRFS (HR, 1.14; 95% CI: 0.90–1.43). However, CCRT + AC did not achieve significant improvements. Conclusions IC with CCRT yields significant survival benefits in terms of OS and DMFS, whereas CCRT with AC fails to achieve any additional benefit in all endpoints. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.